Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
QIAGEN N.V.Eli Lilly
Last price
$50.22$1,306.69
Currency
USD
USD
$10B$1.2T
25.5343.86
$1.97$29.79
0.620.45
$0.35$6.69
0.70%0.53%
Sector
HealthHealth
Employees
5,50050,000
Ticker
$QGEN$LLY
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $QGEN or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.